pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
LILLY · news · pharmadog
← back to LILLY
News mentioning LILLY
309
stories
15d
Zealand Pharma gets its US marketing leader from Lilly; Bexorg turns to Biohaven for CSO hire
endpoints
15d
STAT+: Can ultrasound unlock the power of gene therapy? A startup makes big claims
stat
15d
Predicting biotech clinical trials and a new Alzheimer’s drug controversy
stat
16d
Lilly to buy AtaiBeckley for $2.8B, further validating psychedelics
biopharma dive
16d
Veradermics keeps ‘momentum going’ as baldness drug helps women with hair loss
biopharma dive
16d
STAT+: Brain implant restores the sensation of touch in a person with quadriplegia
stat
16d
Lilly makes up to $3.8B psychedelics play in AtaiBeckley takeover
biospace
16d
STAT+: Pharmalittle: We’re reading about Kalshi bets on clinical trials, a Merck cholesterol pill, and more
stat
16d
STAT+: FDA approves Merck’s oral PCSK9 drug, a first
stat
16d
Braveheart, Attovia, Vogenx keep IPOs ballooning with plans to compete in cardiometabolic, immuno
biospace
16d
STAT+: Kalshi comes for biopharma, with prediction markets for clinical trials and FDA approvals
stat
16d
STAT+: Eli Lilly to acquire psychedelics-focused biotech AtaiBeckley
stat
16d
Lilly bets $2.8B upfront on psychedelics in deal to buy AtaiBeckley
endpoints
16d
Recon: Lilly to buy psychedelic developer AtaiBeckley for up to $3.8B; FDA approves Merck’s novel cholesterol drug
raps
17d
STAT+: Bipartisan lawmakers want to require U.S. to probe reliance on foreign-made drugs, ingredients
stat
17d
Eli Lilly invests in Oura to support patients on GLP-1 drugs
endpoints
17d
STAT+: Glenmark to pay $29.6 million to settle price-fixing allegations in long-running battle with states
stat
17d
J&J dips despite upbeat outlook; AstraZeneca, Spero cut China deals
biopharma dive
17d
STAT+: Pharmalittle: We’re reading about a Biogen Alzheimer’s drug, skyrocketing 340B drug sales, and more
stat
17d
STAT+: FTC settles lawsuit with CVS Caremark over charges it manipulated insulin prices, impeded access
stat
17d
STAT+: Sales from controversial U.S. drug discount program rose to $100 billion last year
stat
18d
Majority of new Ebola cases in eastern Congo are from unknown chains, as outbreak outpaces response
stat
18d
STAT+: Pharmalittle: We’re reading about a battle between Lilly and Teva, psychedelic drugs, and more
stat
18d
Biogen data highlight promise, questions surrounding tau-targeting Alzheimer’s drugs
biopharma dive
21d
Deals, deals, deals; Biohaven takes on Eli Lilly; and more
endpoints
22d
STAT+: Roche ends Huntington’s gene-silencing programs
stat
22d
STAT+: Pharmalittle: We’re reading about bigger drug discounts in Germany, drugmakers embracing secrecy, and more
stat
22d
Whistleblower takes on health insurance and FDA commissioner candidates
stat
23d
Eli Lilly dominates first-half biotech acquisitions, with no sign of slowing down
endpoints
23d
STAT+: Pharmalittle: We’re reading about FDA commissioner contenders, a heart drug failure, and more
stat
← prev
page 4 of 11
next →
